Hereditary Angioedema Therapeutics Market Size, Share and Growth Outlook, 2026

Hereditary Angioedema Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Hereditary Angioedema Therapeutics Market size is forecast to increase from $4.29 Billion in 2026 to $9.33 Billion in 2034 at a CAGR of 10.2% between 2026 and 2034.

The Hereditary Angioedema Therapeutics market report provides detailed analysis and outlook of Hereditary Angioedema Therapeutics segments including By Drug Class (Kallikrein Inhibitors, C1-Inhibitor Concentrates, Bradykinin B2 Receptor Antagonists, Gene and RNA-Based Therapies), By Treatment Strategy Focus (Prophylaxis Treatment, On-Demand ), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online ), By End-User (Hospitals, Specialty Clinics, Homecare Settings) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Hereditary Angioedema Therapeutics Industry Overview

Targeted Therapies Are Transforming Hereditary Angioedema Management

The hereditary angioedema therapeutics industry is experiencing significant advancement as biotechnology and pharmaceutical companies introduce highly targeted treatments designed to prevent and rapidly control recurrent swelling attacks. Hereditary angioedema is a rare genetic disorder characterized by unpredictable episodes of severe swelling affecting the skin, gastrointestinal tract, and upper airway. Historically, treatment options were limited and often required complex administration methods. Today, the industry is increasingly focused on RNA-targeted therapeutics, plasma kallikrein inhibition, and patient-friendly delivery systems that improve disease control, treatment adherence, and quality of life. These innovations are reshaping clinical management strategies and supporting a more personalized approach to hereditary angioedema care.

RNA-Targeted Therapeutics Expand Long-Term Prevention Options

One of the most important developments within the hereditary angioedema therapeutics industry is the emergence of RNA-based prophylactic therapies. Otsuka Pharmaceuticals and Ionis Pharmaceuticals secured regulatory authorization for Dawnzera (donidalorsen) across the United Kingdom and Europe, making it the first RNA-targeted subcutaneous therapy approved for routine prevention of hereditary angioedema attacks in patients aged twelve years and older. The approval was supported by Phase 3 OASIS-HAE clinical findings demonstrating an 81% reduction in attack frequency. By targeting disease-related molecular pathways through RNA technology, donidalorsen represents a new generation of precision therapies designed to provide durable prophylactic protection while reducing treatment burden. The success of RNA-targeted medicines reflects the growing role of advanced genetic and molecular approaches in rare disease management.

Oral Acute Treatments Improve Speed and Convenience

The industry is also witnessing substantial progress in therapies designed for rapid intervention during acute hereditary angioedema attacks. Updated international treatment guidelines have incorporated KalVista Pharmaceuticals’ Ekterly (sebetralstat) as a recommended first-line option for acute episodes. As the first oral plasma kallikrein inhibitor approved for this indication, the therapy offers a convenient alternative to injectable treatments. Clinical data from the KONFIDENT study highlighted the ability of patients to initiate treatment within a median of four minutes following symptom onset due to the portability and simplicity of oral administration. The availability of rapid-response oral therapies is helping patients manage attacks more effectively while improving treatment accessibility in both home and community settings.

Advanced Delivery Systems Enhance Patient Self-Administration

Manufacturers are increasingly focused on simplifying treatment administration through innovative drug delivery technologies. The European Medicines Agency approved Takeda’s new 2 mL pre-filled pen system for TAKHZYRO (lanadelumab), providing a more convenient method for maintenance prophylaxis in adolescent and adult patients. The ready-to-inject device reduces manual preparation requirements and supports easier self-administration of subcutaneous therapy. Such delivery innovations are helping improve patient adherence, reduce administration complexity, and strengthen long-term disease management. The growing emphasis on user-friendly treatment platforms reflects the industry's commitment to enhancing both therapeutic effectiveness and patient experience.

Hereditary Angioedema Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Hereditary Angioedema Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Sanofi S.A., Arrowhead Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Swedish Orphan Biovitrum (SOBI). The Hereditary Angioedema Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Hereditary Angioedema Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Hereditary Angioedema Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Hereditary Angioedema Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Hereditary Angioedema Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Hereditary Angioedema Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Hereditary Angioedema Therapeutics industry include- Takeda Pharmaceutical Company Limited, CSL Limited (CSL Behring), Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc., Sanofi S.A., Arrowhead Pharmaceuticals, Inc., Attune Pharmaceuticals, Inc., Swedish Orphan Biovitrum (SOBI). The Hereditary Angioedema Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Hereditary Angioedema Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Hereditary Angioedema Therapeutics market remains one of the strongest-performing segments in the country.
The US Hereditary Angioedema Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Hereditary Angioedema Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Hereditary Angioedema Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Hereditary Angioedema Therapeutics markets

Canada's strong Hereditary Angioedema Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Hereditary Angioedema Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Hereditary Angioedema Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Hereditary Angioedema Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Hereditary Angioedema Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Hereditary Angioedema Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Hereditary Angioedema Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Hereditary Angioedema Therapeutics sales through 2034

France Hereditary Angioedema Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Hereditary Angioedema Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Hereditary Angioedema Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Hereditary Angioedema Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Hereditary Angioedema Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Hereditary Angioedema Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Hereditary Angioedema Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Hereditary Angioedema Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Hereditary Angioedema Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Hereditary Angioedema Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Hereditary Angioedema Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Hereditary Angioedema Therapeutics Market Segmentation

By Drug Class
Kallikrein Inhibitors
C1-Inhibitor Concentrates
Bradykinin B2 Receptor Antagonists
Gene and RNA-Based Therapies
By Treatment Strategy Focus
Prophylaxis Treatment
On-Demand
By Route of Administration
Intravenous
Subcutaneous
Oral
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Online
By End-User
Hospitals
Specialty Clinics
Homecare Settings

Top Companies in Hereditary Angioedema Therapeutics Industry

Takeda Pharmaceutical Company Limited
CSL Limited (CSL Behring)
Pharming Group N.V.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Sanofi S.A.
Arrowhead Pharmaceuticals, Inc.
Attune Pharmaceuticals, Inc.
Swedish Orphan Biovitrum (SOBI)

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025